Under pressure to help combat this public health crisis, the Food and Drug Administration has begun taking steps intended to reduce overdoses and opioid use disorder, but critics warn against use of controversial DNA test.
Healthcare institutions are implementing artificial intelligence (AI) at a rapid pace. The hope is that AI will improve the quality of care and reduce costs in the long run. However, the deployment of AI in healthcare settings also presents new ethical and legal challenges. For example, AI can reproduce health disparities and pose a risk to patients if human factors, like implicit or explicit bias, are present in the training data set or it lacks representation from population subgroups. AI also raises challenges for regulators like the U.S. Food and Drug Administration (FDA).
Requires coverage of cancer treatment targeting a specific genetic mutation. Prohibits a health coverage plan from denying coverage for a medically necessary drug on the basis that the drug is not indicated for the location in the body of the patient's cancer, if the drug is FDA approved for the treatment of the specific mutation of the patient's cancer. 3/9/2020 Read by title, under the rules, referred to the Committee on Insurance. Bill Status: Pending